Anavex Life Sciences (AVXL)
Develops oral investigational therapies for neurodegenerative and neurodevelopmental diseases.
$2.34
vs last close−0.14 (−5.47%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 40.67% | 37.70M shares | |
|---|---|---|---|
| 188 holders · as of Jun 30, 2026 | |||
| Insiders | 1.68% | 1.55M shares | |
| 2 holders · as of Sep 12, 2025 | |||
| Other | 57.65% | 53.45M shares | |
| remainder | |||
92.70M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
188 holders · 37.70M shares · 26 new positions · 89 increased · 58 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.06M | 8.69% | +446.0K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 4.05M | 4.37% | +190.6K | Aug 13, 2026 |
| Two Sigma Investments, LP | 3.05M | 3.29% | −201.4K | Aug 14, 2026 |
| Geode Capital Management, LLC | 2.41M | 2.60% | +219.2K | Aug 12, 2026 |
| State Street Corp | 1.92M | 2.07% | −2.59M | Aug 7, 2026 |
| Federated Hermes, Inc. | 1.07M | 1.16% | +539.6K | Aug 12, 2026 |
| AQR Capital Management LLC | 963.0K | 1.04% | +206.2K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 948.6K | 1.02% | +165.5K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 5.03% | 4.66M | 13G | Jul 31, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.